Co-Diagnostics, Inc.

CODX

US1897632048

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:00:00 2026-04-10 pm EDT			5-day change	1st Jan Change
1.370 ^USD	-4.86%		-11.04%	-72.91%

Apr. 02	CoMira Diagnostics Receives Approval for Manufacturing Facility in Kingdom of Saudi Arabia's Sudair Industrial City	CI
Apr. 02	Co-Diagnostics joint venture Comira receives approval for manufacturing facility in Kingdom of Saudi Arabia's Sudair Industrial City	RE

Co-Diagnostics, Inc.(NasdaqCM:CODX) added to NASDAQ Composite Index

Published on 03/12/2026 at 01:53 pm EDT

S&P Capital IQ

CO-DIAGNOSTICS, INC.

-4.86%

RUSSELL 3000

-0.16%

Co-Diagnostics, Inc added to NASDAQ Composite Index.

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Approximate price	Change	5d. change	Capi.
	CO-DIAGNOSTICS, INC.	1.370USD	-4.86%	-11.04%	4.94M
	RUSSELL 3000	3,877.18PTS	-0.16%	+2.96%	-

Latest news about Co-Diagnostics, Inc.

Apr. 02	CoMira Diagnostics Receives Approval for Manufacturing Facility in Kingdom of Saudi Arabia's Sudair Industrial City	CI
Apr. 02	Co-Diagnostics joint venture Comira receives approval for manufacturing facility in Kingdom of Saudi Arabia's Sudair Industrial City	RE
Mar. 31	Co-Diagnostics, Inc., Q4 2025 Earnings Call, Mar 31, 2026
Mar. 31	Co-Diagnostics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Mar. 30	Co-Diagnostics, Inc. Auditor Raises 'Going Concern' Doubt	CI
Mar. 25	Co-Diagnostics Ships Diagnostic Materials to India for Initiation of Tuberculosis Clinical Studies Following Recently Issued Guidance from the World Health Organization	CI
Mar. 20	Co-Diagnostics Signs Agreement to Significantly Expand Commercial and Distribution Territory Across South Asia	CI
Mar. 12	Co-Diagnostics, Inc.(NasdaqCM:CODX) added to NASDAQ Composite Index	CI
Jan. 15	Co-Diagnostics, Inc.(OTCPK:CODX) dropped from S&P TMI Index	CI
Jan. 12	Co-Diagnostics, Inc.(OTCPK:CODX) dropped from NASDAQ Composite Index	CI
Dec. 30	Co-Diagnostics to Effect a 1-for-30 Reverse Stock Split	MT
Dec. 17	Co-Diagnostics Performs Analysis of Influenza Co-Primers®? to Confirm Reactivity Against Flu A H3n2 Mutation	CI
Dec. 13	Certain Warrants of Co-Diagnostics, Inc. are subject to a Lock-Up Agreement Ending on 14-DEC-2025.	CI
Dec. 13	Certain Restricted Stock Units of Co-Diagnostics, Inc. are subject to a Lock-Up Agreement Ending on 14-DEC-2025.	CI
Dec. 13	Certain Stock Options of Co-Diagnostics, Inc. are subject to a Lock-Up Agreement Ending on 14-DEC-2025.	CI

Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Companyâ€™s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the userâ€™s mobile device.

Employees

115

Sector

Advanced Medical Equipment & Technology

More about the company